Cantor Fitzgerald Weighs in on VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Stock analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Voyager Therapeutics in a research report issued to clients and investors on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($0.98) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $5.73 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.89) per share.

Several other equities research analysts also recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Wedbush began coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Citigroup began coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Stock Up 2.8 %

Shares of NASDAQ VYGR opened at $5.19 on Tuesday. Voyager Therapeutics has a twelve month low of $5.03 and a twelve month high of $10.66. The firm has a fifty day simple moving average of $5.99 and a 200 day simple moving average of $6.75. The company has a market capitalization of $283.51 million, a PE ratio of 7.31 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter last year, the firm earned ($0.59) earnings per share.

Insider Buying and Selling

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its holdings in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares in the last quarter. Hunter Perkins Capital Management LLC raised its position in Voyager Therapeutics by 3.3% during the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after buying an additional 2,025 shares during the last quarter. Empowered Funds LLC raised its position in Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after buying an additional 2,278 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after purchasing an additional 2,638 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock valued at $804,000 after purchasing an additional 3,473 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.